Sign In
18 Sep 2009 16:29
Cyprotex PLC
("Cyprotex" or the "Company")
Director's Dealing
The Company received notification that Dr Anthony Baxter, Chief Executive Officer of the Company, acquired 121,400 ordinary shares in the Company on 18 September 2009 at a price of 4.45 pence per share. As a result of this purchase, Dr Baxter has an interest in 721,400 ordinary shares in the Company representing approximately 0.40 per cent. of the Company's total voting rights.
For further information:
|
Cyprotex PLC |
Tel: +44 (0) 1625 505 100 |
|
|
John Dootson, Chief Financial Officer |
||
|
ir@cyprotex.com |
www.cyprotex.com |
|
|
Noble & Company |
Tel: +44 (0) 20 7763 2200 |
|
|
John Llewellyn-Lloyd john.llewellyn-lloyd@noblegp.com |
||
|
Sam Reynolds |
||
|
sam.reynolds@noblegp.com |
www.noblegp.com |
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
|
Ben Brewerton / Ben Atwell / John Dineen |
||
|
cyprotex@fd.com |
www.fd.com |
|
CRX.L (CRX)
Follow the stocks
